Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
    • FemmeBreaking barriers and building confidence in investing
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • Investing SchoolGuides and lessons to grow your investing knowledge
    • Portfolio buildersInvesting knowledge for every level, from first steps to advanced portfolio strategies.
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Transcripts

Read transcripts of webcasts and audiocasts

Transcripts

Read transcripts of webcasts and audiocasts

All regions
Finland
Sweden
Denmark
Norway
Latest
Trending
Followed

Medicover, Audiocast, Q2'26

By Inderes7/22/2026, 7:30 AM
Medicover

Disclaimer: This is a machine-generated transcript and may contain inaccuracies.

John Stubbington
00:02 - 16:28

Morning, everybody. It is John here. Welcome to our Q2 2026 report. I think we have had a quarter of positive progression, which we are very pleased with. You can see it's another quarter of double-digit organic revenue growth and margin expansion, which is really what we're aiming for. Strong organic growth of 11.8%. And this is our sixth quarter of improved margins. So we are very pleased with that. It's a record that we're proud of and hope to continue as we go forward. Just a reminder for everybody, this particular quarter has a very strong comparable base. Last year we made significant movements upwards. So it's even more pleasing to see the progress that we've actually made. And a year or so ago, probably just a year and a quarter, there was a lot of talk about India and what we were going to do in terms of the growth for India. But you can see that over Q1 and Q2, we've had very positive progression and really strong growth percentages. Our diagnostic services business has performed very well. There is a level of consistency happening within that division, which we are delighted with. And it is all credit to their hard work. And we have consistency of increasing our fee-for-service revenue streams, which is where our main focus is. And leverage was at 2.9. So revenue is 640.4 million, which is very respectable in terms of the growth rate. You can see that from an organic perspective. It is 11.8%, which is very credible indeed. Adjusted EBITDA was 109.2, which is very pleasing to see and reflects our progress. And you can see also with the Adjusted EBITDA margin at 17.1%, the increase there is not as big. But as I said, there is a very high comparable. So just to see that move in the right direction is very positive for us. Operating cash flow was 73.6 million. That is up 28.44%. So really good generation. From our perspective, that is quite important for us because as we do that, it gives us more choices. Leverage, as I said, is at 2.9, that is down from where we were at year end at 3.1. And of course, it's improved quite considerably if we look year on year from 3.6 last year to 2.9. So, we have produced a good, solid set of numbers. We are happy with that if we move forward and just look at the revenue and the progression of the revenue streams. Another good quarter. Revenue produced at expected levels. So we are happy with that. Revenue by country is very steady. But you can see a strong quarter in India in euros up 23%, and in local currency much higher. As I said, at this time last year, it was a big area of debate for us. So it is really pleasing to see the team have continued their progress and have momentum inside that business and revenue by payer. A little bit of change in mix is happening here with different things going on, but very good strength is coming through from fee for service, which is our biggest stream. And it's obviously the stream that we want to concentrate on a lot. And it's good to see that growth in governmental revenue streams in terms of public pay, as there are lots of micro changes happening there that are affecting it. And we know that in terms of our funded business, we want to continue to develop that, but it is pleasing to see that we have got growth starting to come through in Poland from some of the initiatives that we have put in place. So that's very, very positive. If you look at healthcare services, there was solid performance by healthcare services; again, this is the area where the comparable base was likely the highest. So, we need to bear that in mind, but revenue growth was 6.9%, with organic growth of 12.2%. So, very, very good. And price accounted for 55.2% of that. So, you know, quite a solid mix that we have there, as I said, with India, 23.1% revenue growth in India in euros, but 39.6% in local currencies. So 34.4% last quarter towards 40% this quarter. Good momentum in that particular business. Fee for service and other areas performed well. Sports and wellness continues to be strong for us. And we will continue to develop that proposition very strongly. Memberships remain relatively unchanged. As I say, Poland grew, while there was some membership fall in Romania. Quite a bit of that was contract management. As we manage the profitable and unprofitable accounts, most importantly related to the fee for service, our ability to create relationships with people looking for those kinds of solutions is growing quite strongly. Revenue was 442.8 million. So, 6.9 percent is a good EBITDA margin. 18.4%. So a slight change there against the comparable membership. Memberships are relatively flat and revenue by country is not changing dramatically. When you see the minuses, please bear in mind that we still have Hungary in these comparables. So that affects that particular indicator, and as we move to diagnostics, we will see that it's a strong growth and improved profitability. So, congratulations to that team. Good revenue growth increased by 8.5 percent, and organic growth was up 10.9 percent. And a good proportion of that is in price. And please remember that from a German perspective, the ability to move prices is almost absolutely zero. So, very credible performance by the diagnostics team. Fee-for-service. Strong. As we said, that is the area of focus. So that is really pleasing to see operational leverage coming through. And of course, with the diagnostic tests, the mix is quite important in terms of the different types of tests that you do. We have always focused on making sure we have a reputation for not only covering the basics but also covering the more advanced side of healthcare. So that's great. Ukraine continues to deliver a really solid performance for us. I mean, Q1 we said was softer. A bit of that was reflected by the weather, but that was also reflected by the war conditions. But considering the things that they have to overcome, we just have such a fantastic team in Ukraine and we would like to thank them for everything they do because it really is difficult conditions that I don't think any of us would want to trade. And Germany did really, really well. Solid momentum. We are seeing the change in mix continue where we are getting more fee-for-service revenue. Maybe as a consequence of the environment, but also a consequence of the varied proposition that we have there. Our expansion on BDPs continues, and it is really important for us in terms of the future. So that is very good to see. The number of tests is up by 4%, which is good progression; 40.3 million tests were produced, which generated very solid revenue of 205.1 million, up 8.5%. So very good continued improvement in the margin. You can see that that is a significant improvement the team has achieved there. So, very pleasing to see. 40.3 is a positive sign against our 38.7 tests of the comparable quarter. And if you look through from a country mix, it is again relatively stable. And you can see the strength of Ukraine coming through with that. And again, our payer mix continues to increase on a fee-for-service basis. And that will give us much more stability and, of course, opportunity to move prices as we move forward. So, very positive signs. So congratulations to everybody in Diagnostic Services. So I will hand over to Anand, who will talk you through a little bit more detail on the financials. And then I'll come back at the end to summarize. Anand, over to you. Thank you, John. I'll describe the quarter as a solid quarter with consistency in us delivering double-digit organic revenue growth and margin accretion as well. So we are pleased with our numbers. I think one number I would highlight is EBIT. So EBIT of 51.2 million. You can see our margin rate is 8% now, which is up 100 basis points year-on-year. So pleased to see underlying profitability being boosted by, as John said, in some areas, tough comps, but we are still growing our margins year-on-year and our organic revenue growth as well. Other profit measures are up year on year as well. As you can see from the page. One I will pull out is EBITDA, which is obviously our best measure of cash profit at 72.7 million. That is up just under 13%, with margin accretion of 50 basis points year-on-year at 11.3%. So we are pleased with that. And as a reminder, in Q2, we paid our dividend of €0.20 per share. That is reflected in our cash flows. From a healthcare perspective, John mentioned that we had some tough comps from last year but we are still pleased with the growth. I would say it was a solid performance. So organic revenue growth of 12.2%. And you can see there was growth in both price and volume, which is very pleasing from an Adjusted EBITDA perspective. It is up year-on-year at 55.6 million. There is margin rate dilution year-on-year of 30 basis points. That is predominantly due to the tough comparables, as I mentioned earlier. And there is also some one-off activity from last year, which if you strip out, then we would be up year-on-year. EBITDAaL relating to the immature Indian hospitals. You can see the loss on those in the quarter was 3.2 million. So it's down a bit on last quarter, but up on last year; those are predominantly due to the hospitals that we opened in Q1, and in line with expectations. But as John Stubbington says, we're pleased to see the India overall company performance perform really well at the numbers that he mentioned earlier. I'd say a very strong month from diagnostics, so solid in healthcare; strong in diagnostics, so organic growth at 10.9%. Again, pleasing to see volume growth as well as price growth across both. EBITDA of 30.3 million, which is very strong with margin rate expansion of 110 basis points at 14.7%. I think obviously, we kind of concluded on the two acquisitions we did in Q2 last year, and it's pleasing to see in both healthcare as well, actually, and in diagnostics, that the synergies we've realized are helping boost our numbers year on year. In other metrics. So leverage trends down. So it is below three, which is good compared to last year, as our increasing profitability offsets the fact that we are keeping our invested base safe from a debt capital and equity capital perspective. You will have seen that we increased and strengthened our liquidity in Q2. So in May, we managed to increase our RCF from 300 million to 400 million. That gives us more scope, optionality, and headroom to take further investment decisions in the future, should we choose to. I've mentioned the dividend we paid of €30 million in Q2; taxes were in line with expectations at 28%, and there was improved performance in cash versus Q1, with net operating cash flow at €73.6 million, and free cash flow at 4.1% of revenues versus 3% last year. And finally, on ROIC, there is an improvement there as well. So 13.6% versus 9.3% last year. So. So, I'd say a good performance on those measures. In terms of CapEx, if you look on the left, you can see this clear blue water between our free cash flow and our growth CapEx, which is good. Our CapEx overall was 29.7 million in the quarter, about 4.6% of revenues. I've mentioned previously that this will be around 6% of revenues for the full year, and we'll stick to that in terms of the type of spending where the money was spent in the quarter; two-thirds was in healthcare services and a third in diagnostics. The maintenance-growth split is 44% to 56% in this quarter. However, looking forward for the full year, we expect to see it revert back to more two-thirds on growth and a third on maintenance. And finally, medical space of just over 1,000,000 square meters. This will move in the quarter, but it is up year on year. And finally, with regards to our mid-term targets to 2028, we still expect to achieve them. So, organic revenue of 3.25 billion, adjusted organic EBITDA of 600 million, leverage under three, and all the other measures highlighted in the bottom right corner, including EBITDAaL. We expect to achieve that for now. So with that, I'd like to say thank you. And I'll hand back to John to wrap up. Yeah. We say here solid performance. And that's probably our Englishness that's coming through there. It is really good to see the consistency that we have got with the double-digit organic growth, six consecutive quarters with margin improvement, which is the zone that we want to be in with strong FFS revenue growth. Yeah. That is one of our most important revenue drivers. Really good to see that the synergies from the two acquisitions, which were our largest in our history, have come through and the acquisitions have been embedded well into the organization. And they are very much part of Medicover now. India, as I said before, has been the subject of a lot of conversation. If we go back 12 months, we said that we would start to see the momentum of that coming through. And it is coming through. So strong double-digit revenue growth, even in euro terms with the exchange rate. So, congratulations to all. And we will do what we've said that we're going to do; we'll focus on our execution. We'll focus on making sure we get efficiency, improving our capacity utilization and making sure that when it comes to our price and cost management, that we take the appropriate steps. That means that the customer gets what they need. And that we have a good, strong, sustainable business. And finally, a thank you to all of the people at Medicover; these results have been created due to your hard work. So thank you very much for all you do. Okay. And now we'll go to the Q&A and hand over to the moderator to help us with that.

Operator
16:30 - 16:48

If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Christopher Lilleberg from DNB Carnegie. Please go ahead.

Christopher Lilleberg
16:50 - 17:12

Hi. I have some questions here regarding Poland and then India as well. So Poland first, would you be able to comment on what growth would have been adjusted for the strength in the sport and wellness segments? I am thinking about both funded and the fee-for-service, adjusted for sport and wellness, which seems to be performing very well.

John Stubbington
17:14 - 17:21

No, we don't disclose that information. Christopher. So unfortunately, I cannot answer that question. We do not do it for competitive reasons.

Christopher Lilleberg
17:23 - 17:33

Okay. And you said funded, we're growing again in Poland. Is that also true for members quarter over quarter?

John Stubbington
17:33 - 18:08

Yes. Yeah. Our funded position has started to move again in Poland. We've put, as we commented on previous quarters, we've put some different solutions out there in the market and more are going to come. We fully expect the employment market to help us along as well. But even whilst that has been adjusting a little bit, that is probably the best way to describe it, that we still know that we can penetrate more. So, we expect to do more on that line as we move forward.

Christopher Lilleberg
18:11 - 18:20

But given that the number of members was down here sequentially, it seems like a fairly large drop in Romania, if you could please explain that a bit.

John Stubbington
18:20 - 19:14

We looked at our profitability on the portfolio and made some harsher decisions in terms of the membership that we have in the portfolio in Romania. So it did drop, and what we have to remember about Romania is that currently there are quite a lot of fiscal changes happening. And there are some other companies that decided that healthcare is not right for them at this moment in time, but membership is not the biggest part of our business down in Romania. It is a much smaller percentage of our revenue mix. I think that will stabilize as we move forward. So we have to watch it briefly. We are taking counteractions. But regarding your question about Poland, we expect Poland to be, as in history, relatively strong for us.

Christopher Lilleberg
19:16 - 19:33

Okay, great. And then, India, if you could comment on margins there, I don't know if. EBITDA versus the rest of the group, is it improving year-over-year? Yeah. Anything.

Anand Patel
19:34 - 20:06

Yeah. I think broadly speaking, they are slightly up year on year. But we are more pleased about the revenue growth, as always, with building margin in, let's say, Indian hospitals where I've seen you recruit the doctors first and then the revenues tend to follow. We have a strong base of having recruited a good set of doctors. And now the revenues are starting to follow, as you can see. We expect a bit of margin accretion further. Yes, we are pleased.

Christopher Lilleberg
20:07 - 20:12

But is it true then that India margins are still dilutive for the business?

Anand Patel
20:12 - 20:14

Business? Yes.

Christopher Lilleberg
20:14 - 20:29

Okay. And just when it comes to the impact on EBITDA margin from leases, is that a similar effect to what you have in Europe? If we look at it as a percentage of sales or something like that.

Anand Patel
20:30 - 20:37

It is similar. Yes, I would say yes, because obviously the rupee has depreciated year on year as well. So yes.

Christopher Lilleberg
20:38 - 20:39

Okay, great. Thank you very much.

John Stubbington
20:40 - 20:41

Thank you.

Operator
20:44 - 20:48

The next question comes from Matthias from SEB. Please go ahead.

Matthias
20:49 - 21:16

Yes. Hi. I have a couple of questions. Starting with Romania, I think the macro backdrop was quite well explained. What would be helpful, I think, is some more flavor on the political situation and perhaps more. Yeah. What tangible initiatives are being taken there to impact your ability to grow? And maybe, if it will be sort of soft on a year-on-year basis also for H2 2026. That is the first one.

John Stubbington
21:18 - 23:16

Yeah. The political situation down there creates a degree of instability. That translated into some micro changes in the payment system in healthcare from the governmental funds, where they have capped things which historically weren't capped before, cut some of the tariffs, and are basically repurposing the framework to be able to balance budgets and come into line with things. So, these changes occur. And then for us, we feel it, because in that location, over time, what we would expect to happen and usually does happen is that the people that are not getting their care through that means will switch to getting their care through an alternative means. So we have to repurpose our operations as these things happen, and we are taking those kinds of countermeasures in terms of the offerings that we do for fee-for-service and the way that we look at the lines that have been affected from a governmental perspective. And then usually what happens is our fee for service line starts to attract more people as a consequence, and we start to move through it; ultimately, the government of Romania has a responsibility to provide care to the people of Romania through the governmental funds. They will continue to do that. It is just that there are micro changes happening that we have to adapt to. So, it will take a bit of time for us to adapt, but we should be able to come through that. I would like to add one more thing. And usually, that creates opportunity for us. So, let's see how it plays out.

Matthias
23:18 - 23:37

Yeah. Thanks. Good. A good example of that, I guess, is Germany, and as you were saying, you had better organic revenue growth year-on-year in Q2 compared to the first quarter. Would you say this is just more patients moving to the FFS line that is helping you there, or is it anything else?

John Stubbington
23:38 - 24:54

No, I think it is a combination of a number of factors, as it always is in our business. It is not really down to one particular answer, but rather due to the nature of what we do. But yes, the nature of the reforms that happened a year ago would have changed consumer behavior to be more prepared to pay out of pocket because of delays. We do not expect that to be like a tap, which did not have a lot coming out of it. And suddenly there is a significant volume coming out of it. We expect that to move over a period of time. But I think the strength of our broad portfolio of testing and the fact that we have lots of tests that are very much focused on the medical side of life and supporting the medical profession, but also within our portfolio, we have more lifestyle-related things, which are becoming more and more popular. So I think we're well placed to be able to take advantage of those positions and see fee for service progress. But don't expect it to be a dramatic change. It should be steady as we go, and as we see the trends and understand where to focus, we will very much seize on that.

Matthias
24:56 - 25:13

Thanks. I will squeeze in one last question. In terms of the price contribution in diagnostics, it has been averaging around 3.1% since the onset of 2025. Now I think it was 5%. What is driving that? I think it is in Germany. No changes, I presume.

John Stubbington
25:14 - 25:14

Yeah.

Matthias
25:15 - 25:18

Could there be any impact from raising prices in FFS for Germany?

John Stubbington
25:18 - 25:37

Maybe not. No, I don't think so. I do not think that any price change that we do in Germany happens because there are frameworks that control things. So no, it is much more mixed. Yeah. And the strength, as I said, of the broad nature of our portfolio.

Matthias
25:39 - 25:40

Thank you so much.

John Stubbington
25:40 - 25:40

Thank you.

Operator
25:43 - 25:47

The next question comes from Kane Slutzkin from Deutsche Bank. Please go ahead.

Kane Slutzkin
25:50 - 26:10

Good morning. Morning. Just a quick one. I am not sure if you can comment, but can you talk to the situation around the Indian business? I mean, originally you were looking to list this business. But I guess in June we learned of talks with KKR regarding a potential sale. Where are we on these discussions? Thanks.

John Stubbington
26:11 - 27:26

Yeah. As you can expect, I cannot say too much on this from a legal perspective; I can just reiterate the facts for everybody, which is, as everyone knows, some time back we said we would explore the IPO in India. You know, that still very much is an option for us. And we are continuing to do the work on our IPO. At the same time, our business in India is very attractive. It is no surprise or shock to us that people have knocked on our door. Our responsibility, if somebody does that, is for us to evaluate things and see what is the best course of action for us. And of course, one person knocking on the door does not mean there could not be other people who would want to knock on this door as well. So it is a good position that we find ourselves in. We have a very attractive business and different options that we could deploy. No decisions have been made on options. As I said, we have a responsibility to evaluate, and we are in that process. So that's really all we can say at this moment in time.

Kane Slutzkin
27:29 - 27:29

Thank you.

Operator
27:34 - 27:39

The next question comes from Darius Saftoiu from Jefferies. Please go ahead.

Darius Saftoiu
27:41 - 28:13

Hi. Thank you for taking my questions. I hope this time the line is better. First on India, I would like to ask, given the strong local currency growth in Q1 and Q2 and of course, the new hospital opened in Q1, if you could provide some color on when you expect the startup losses to peak and when we should see a meaningful reduction in the drag from newer hospitals? And could you also provide some color excluding this new hospital in Q1? How was the progression there?

John Stubbington
28:15 - 29:47

The great news is that the line is very clear this quarter. So that is very positive. The trend of opening new hospitals and the period before the drag disappears is different hospital by hospital because a lot depends upon the size of it, the scale of it, the mix of the specialisms and your ability to get various licenses approved and your recruitment. What kind of doctors have you recruited? Are they big hitters? Are they people who are going to take a little bit longer to be able to build up your revenue stream? So it is very difficult to say the model is exactly this. But we have made very good progress in terms of our openings, and if you look back in history, you will see that there has always been a drag. And that quarter-on-quarter, as we've reported that drag, that drag has tended to reduce if we haven't opened any new hospitals. And of course, in this period, we have opened a couple of new hospitals in India, which in our IPO program were the final two that we were looking to do. So what you would expect to see is that as we go by each quarter, seasonally adjusted, of course, you would expect to see that drag just reduce over time. And, over a period of 18 months to two years, that starts to be less significant.

Darius Saftoiu
29:50 - 30:14

Yeah. Thank you. And my second question on the FFS revenue momentum in Q2 accelerating, if you could discuss the momentum in Germany versus Poland and Romania, and also provide some color on how you see the differences between volumes and pricing going forward, given inflation has been more stabilized in Germany and Poland versus higher inflation in Romania.

John Stubbington
30:16 - 31:49

Yeah. We have a stance that we have repeated a number of times when it comes to pricing, which is that our position is that we want to provide high-quality healthcare to the people that entrust their money with us, and as they come to us, we give them the care that they need to get the effective outcome. If that means that we have to adjust prices to be able to pay our resources appropriately, then we will do that. So we have a history of making sure, whether it is funded or whether it is fee-for-service, of adjusting price to the market conditions. If you look back historically, we have relied a bit more on price adjustments in our revenue growth. This will balance out because the inflationary period that we had in history was much, much higher. That inflationary period is now starting to wash through. And although there will always be inflation in healthcare, which is always higher than the average inflation, it is not as high as it was historically. So you can expect the pricing and volume mix to balance out a little bit depending upon the line.

Darius Saftoiu
31:51 - 32:09

Yeah. Thank you. And if I may have one last short question regarding the recent heat waves across Europe, have you observed any postponements in surgeries, appointments, or testing? Could you provide some color on the end of Q2 or not?

John Stubbington
32:09 - 32:23

In our first six months of the year, we have been affected by weather more than anything else. But no, we haven't seen any dramatic change in trends created by events. So no.

Darius Saftoiu
32:26 - 32:27

Thank you.

David Gorzynski
32:27 - 32:28

Thanks a lot.

Operator
32:30 - 32:34

The next question comes from Christopher Lilleberg from DAB Carnegie. Please go ahead.

Christopher Lilleberg
32:37 - 32:44

Hi. Yes, a quick one on the tax rate. Have you commented on what tax rate you expect for the full year?

Anand Patel
32:45 - 32:52

I believe the guidance I provided was between 26% and 30%. So, yes. Okay.

David Gorzynski
32:53 - 32:53

Thank you.

Operator
32:55 - 32:59

The next question comes from Mathias from SEB. Please go ahead.

Matthias
33:03 - 33:18

Hi, one follow-up: the tie-up in working capital year-to-date this year versus the first six months of 2025 is a bit higher. Is there anything in particular that is driving that? Yeah. Is it expected to normalize going forward? Thank you.

Anand Patel
33:18 - 33:23

Sorry, Mathias, I didn't hear you. Did you say working capital? Is that what you said?

Matthias
33:23 - 33:32

Yeah. The tie-up in net working capital year-to-date figure this year is a bit higher than last year. I just wanted to see if there is anything in particular or if it is.

Anand Patel
33:32 - 33:59

No. No. Yeah. Nothing particularly in terms of one-offs or anything like that. I think it's just due a little bit to the mix of our business. Right. So as we do more, let's say government-led business, either in India or in Poland, then they naturally have longer terms in terms of securing our payments. So, that is it. Aside from that, there is nothing specific to pull out in terms of working capital.

Matthias
34:00 - 34:01

Thank you so much.

Operator
34:05 - 34:10

The next question comes from David Gorzynski from PKO BP Securities. Please go ahead.

Christopher Lilleberg
34:13 - 34:13

Hi.

Matthias
34:14 - 34:15

Thanks for taking my question.

Christopher Lilleberg
34:15 - 35:15

Actually, I have three questions. The first one, again, relates to the EBITDA loss from India regarding new hospitals. And you said that the majority of this quarter's loss, which was 3.23 billion if I'm right, was related to the new hospital opened in the first quarter. And when we compare it to the approximately 3 million in the fourth quarter, there was no impact of the. This new hospital. Does that mean? Or is my conclusion correct that the loss from other hospitals opened in the last two years was close to zero? Is this for the second quarter?

Anand Patel
35:16 - 35:45

Um, yeah. So look, I cannot answer the question exactly, but I think over about two-thirds or so, at least of the 3.2 million is driven by the new hospital. It is a very big hospital, 14 floors. Is it? So I think it is the tallest hospital in Hyderabad. Yes, the others are performing broadly in line with where we expect on their recovery curves versus the new one we just opened, which is a big one. Okay.

Christopher Lilleberg
35:45 - 35:46

Thanks so much.

John Stubbington
35:47 - 35:56

There was another hospital opening as well that happened in that fourth quarter, so there are two. Yep.

Matthias
35:57 - 35:57

Mhm.

Christopher Lilleberg
35:58 - 36:34

Okay. Okay. I have two questions on the Polish market. So first, on the diagnostic business, there are several government programs right now, including the Profilaktyka 40 Plus program. And last year there was the Prevention 40 Plus program. And I wonder what is the net impact of these programs on your revenue dynamic in Poland?

John Stubbington
36:36 - 36:42

We don't really comment on that, but everybody in the market knows that last year's program was more generous than this year's program.

Christopher Lilleberg
36:48 - 36:51

Sorry, can I just confirm last year?

John Stubbington
36:51 - 37:07

Sorry, sorry, Sorry, I went too fast. I went too fast. We don't really comment on the specifics, but as a general matter, everybody in the market knows that last year's program was more generous than this year's program in general terms.

Christopher Lilleberg
37:10 - 37:56

Okay. Thanks. Thank you. The last issue regarding the recent plans from the Polish government to cut wages for the highest-paid doctors is that do you think it will have any impact on our wages in Poland? I also wonder if you see any shift resulting from the reduction in the number of procedures performed by public healthcare, and a potential shift to private healthcare. What do you think about that?

John Stubbington
37:56 - 39:30

Yeah. I mean, there were quite a number of concepts that were talked about in recent weeks in relation to Poland. You have to put this into the context of the way we have run our business for the last 30 odd years, which is that constantly over that period, different governments and different people within those governments have wanted to make changes in the healthcare system to be able to manage it more effectively for that particular country. One of our strengths as an organization over the 31 years that we have been trading is that as these things have happened, we have been close enough to understand what is happening, what the implications are for us, and how we repurpose. Yeah. So how do we move our operations around to be able to make sure that whatever changes are put in place, we can adapt. That means that we are here for the long term and we have a sustainable business. So this is business as usual to us. There are some specifics in that particular set of changes that people talk about. We will work through those specifics. But currently, from our perspective, it's business as usual. Some of these changes will come in, we will adjust and we will move forward. So we are confident that we will be able to navigate the situation when these changes happen. There are very positive things that can happen to our business if we repurpose in the right way. And that is what we expect to do.

Christopher Lilleberg
39:32 - 39:34

Okay. Thanks so much.

David Gorzynski
39:34 - 39:35

Thank you.

Operator
39:41 - 39:48

There are no more phone questions at this time. So I hand the conference back to the speakers for any written questions and closing comments.

John Stubbington
39:51 - 40:46

There are a few questions that have come through online, so we will try and answer those before we close out. So people are asking for a bit of flavor in terms of the drivers in India, which is moving the growth up; as before, it is a lot of recruitment of new doctors. Those new doctors now are becoming established with us. That is driving the revenue. So that's the main question that's come through. So I'd like to thank everybody for their time this morning. We are very pleased with the results that we have generated for Q2. We think we have a solid base to be able to move forward. Yes. There are some changes in our markets, which could be quite exciting for us. So we're looking forward very much to talking to you in a quarter's time to see how we're progressing. So thank you very much.

Continue to the webcast
Revenio Group Oyj, Q3'26
Language: English11/12/2026, 1:00 PM
Jukka Kainulainen Good afternoon, and welcome to the Revenio Group Corporation Q3 Earnings Call. My name is Jouni Toijala. I am the CEO. And then, again today we have Jukka Kainulainen, our CFO, on th…
Kamux, Q3'26
Language: English11/12/2026, 9:00 AM
Katerina Heterant Good morning. Welcome to the Kamux Q3 results presentation. My name is Katerina Heterant and I am Head of Investor Relations at Kamux. Today we shall go through the Q3 results presen…
Koskisen, Webcast, Q3'26
Language: Finnish11/12/2026, 8:00 AM
Jukka Pahta Hyvää huomenta ja tervetuloa tähän osavuosikatsaustilaisuuteen! Koskisen tammi–syyskuun osavuosikatsaustilaisuuteen lähdetään otsikolla: Koskisen liikevaihdon kasvu jatkui. Kohonneet kusta…
Reaktor, Q3'26
Language: Finnish11/11/2026, 9:00 AM
Pekka Horo Oikein hyvää aamupäivää kaikille ja tervetuloa tähän meidän webcastiimme. Olen Pekka Horo, Reaktorin toimitusjohtaja, ja kanssani täällä on tänään Antti Akkanen, joka aloitti lokakuussa Rea…
Savox, Q3'26
Language: English11/10/2026, 11:00 AM
Paulina Tanila Our speakers today are CEO Jerry Kettunen and CFO Juha Järvi. Jerry will give an overview of Savox as a company and go through the highlights of the quarter. After that, Juha will conti…
Raisio Oyj, Webcast, Q3'26
Language: Finnish11/10/2026, 10:00 AM
Elli Siltala Hyvää marraskuista päivää Raisiosta! Ja tervetuloa Raision tammi-syyskuun 2026 osavuosikatsauksen webcastiin! Pahoittelut pienistä teknisistä haasteista, mitä meillä oli tässä alussa. Min…
Mandatum Oyj, Audiocast, Q3'26
Language: English11/10/2026, 9:00 AM
Lotta Borgström Good morning, everyone, and welcome to the Mandatum Q3 2026 audiocast. My name is Lotta Borgström from Investor Relations. Joining me today are our CEO, Petri Niemisvirta, and our CFO,…
Solar foods Go-to-market Update
Language: English11/9/2026, 12:00 PM
Maria Hello everyone, and welcome to the Solar Foods go-to-market update. My name is Maria and I'm here today with our CEO, Rami Jokela, and CFO and Deputy CEO, Ilkka Saura. Also with us today is Heli…
Outokumpu, Webcast, Q3'26
Language: English11/6/2026, 12:30 PM
Johan Welcome to the third quarter results webcast. I am responsible for investor relations. We will start with the presentation from our CEO, Kati ter Horst, and our CFO, Marc-Simon Schaar. After the…
Endomines, Webcast, Q3'26
Language: English11/5/2026, 1:00 PM
Andy Turpin Hello, everyone, and welcome to Endomines' third-quarter results webcast. Thanks for joining us today. My name is Andy Turpin and I am the Chief Communications Officer here at Endomines. A…
Lemonsoft Oyj, Q3'26 webcast
Language: English11/5/2026, 11:00 AM
Unknown 1 Welcome to the Lemonsoft Q3 results presentation. We will start with the presentation from CEO Alpo Luostarinen, followed by the Q&A. You can send your questions throughout the event via the…
Enersense, Webcast, Q3'26
Language: English11/5/2026, 10:30 AM
Liisa Tamminen Hello and welcome to the Enersense Q3 2026 results webcast. My name is Liisa Tamminen from Enersense Investor Relations. And with me here I have our CEO, Kari Sundbäck, and CFO, Jan-Elo…
Sitowise, Q3'26
Language: English11/5/2026, 10:00 AM
Mari Reponen Good day everyone, and welcome to the Sitowise Q3 2026 results audiocast. My name is Mari Reponen, and I am responsible for strategy and IR here at Sitowise. And today with me are our act…
Orthex, Webcast, Q3'26
Language: English11/5/2026, 9:00 AM
Alexander Rosenlew Good morning and welcome to the Orthex Interim Report. My name is Alexander Rosenlew and with me I have Saara Mäkelä, CFO, and Hanna Kukkonen, our CMSO. We will take you through the…
Suominen Oyj, Q3'26
Language: English11/5/2026, 8:30 AM
Anni Luoma Good morning, everyone, and welcome to the Suominen Q3 webcast. My name is Anni Luoma. I am the Manager of External Communications and Investor Relations at Suominen. Here with me are our P…
Lumo, Webcast, Q3'26
Language: English11/5/2026, 8:00 AM
Niina Saarto Good morning, all. Welcome. This is Lumo Homes plc's third quarter result webcast. I am Niina Saarto from Treasury and Investor Relations. Today I have two gentlemen here with me, namely…
CapMan, Webcast, Q3'26
Language: English11/5/2026, 7:30 AM
Charlotte Good morning and welcome to this presentation of CapMan. Q3 2026 interim report. Presenting today we have Pia Kåll, CEO of CapMan. And after the presentation, we will have a Q&A session. You…
Marimekko, Webcast, Q3'26
Language: English11/4/2026, 12:00 PM
Anna Good afternoon. My name is Anna and I am the IRO of Marimekko. It is my pleasure to welcome you to our Q3 webcast. With me, I have our president and CEO, Tiina Alahuhta, who will walk you through…
Administer, Webcast, Q3'26
Language: Finnish11/4/2026, 9:00 AM
Kimmo Herranen Welcome to the Administer Q3 2026 interim report. Results. Meillä on se alkaa. I am Kimmo Herranen. Kalle Lehtonen. Also. Kaarina og. Yelken. Kalle Lehtonen En el coco. Madan. Parannus.…
Kempower, Webcast, Q3'26
Language: English11/4/2026, 8:30 AM
Unknown 1 Powering the planet. Kempower. We charge our planet for the better. By powering the electric movement. We enable quick and scalable EV charging solutions for everyone and everywhere. We ma…